China Nuokang Bio-Pharmaceutical Inc. to Reconvene Adjourned Extraordinary General Meeting of Shareholders

China Nuokang Bio-Pharmaceutical Inc. to Reconvene Adjourned Extraordinary
General Meeting of Shareholders

BEIJING, Jan. 29, 2013 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical
Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company") announced today that it will
reconvene the extraordinary general meeting of shareholders (the "EGM") that
was previously adjourned on January 15, 2013. The EGM will be reconvened at
9:30 a.m. (Beijing time) on February 6, 2013, at 26th Floor, Gloucester Tower,
The Landmark, 15 Queen's Road Central, Hong Kong, to consider and vote on,
among other things, the proposal to authorize and approve the previously
announced agreement and plan of merger (the "Merger Agreement") dated
September 27, 2012, among the Company, Kingbird Investment Inc. ("Parent") and
Kingbird Mergerco. Inc. ("Merger Sub"), and, solely for the purposes of
Section6.16 thereof, Anglo China Bio-technology Investment Holdings Limited
and Britain Ukan Technology Investment Holdings (Group) Limited, and the plan
of merger required to be filed with the Registrar of Companies of the Cayman
Islands, substantially in the form attached as Exhibit A to the Merger
Agreement (the "Plan of Merger") and the transactions contemplated thereby
(including the proposed merger).

About China Nuokang Bio-Pharmaceutical Inc.

China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading
biopharmaceutical company in China focused on the research, development,
manufacture, marketing and sales of hospital-based medical products. The
Company provides a diversified portfolio of products across more than 4,200
hospitals in China Nuokang's principal products include Baquting®, China's
leading hemocoagulase product by market share, Kaitong®, a lipid emulsion
alprostadil product for the treatment of peripheral vascular diseases,
cardiocerebral microcirculation disorders and post-surgery thrombosis; and
alpha lipoic acid capsules, or ALA, an antioxidant product that addresses
diabetic neuropathy. The Company's product pipeline includes product
candidates under development in hematological, cardiovascular and
cerebrovascular disease diagnosis, treatment and prevention. Please visit for more information.

Forward-Looking Statements

This press release contains forward-looking statements relating to the
potential acquisition of the Company by an affiliate of Mr. Baizhong Xue, the
Chairman and Chief Executive Officer of the Company. These are
"forward-looking" statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, and as defined in the U.S. Private Securities
Litigation Reform Act of 1995. The actual results of the transaction could
vary materially as a result of a number of factors, including: uncertainties
as to how the Company's shareholders will vote at the extraordinary general
meeting; the possibility that competing offers will be made; and the
possibility that various closing conditions for the transaction may not be
satisfied or waived. These forward-looking statements reflect the Company's
expectations as of the date of this press release. The Company does not
undertake any obligation to update any forward-looking statement, except as
required under applicable law.

CONTACT: China Nuokang Bio-Pharmaceutical Inc.
         Mr. Steven Duan
         Vice President of Investor Relations
         ICR, Inc.
         Mr. Rob Koepp
         Tel: (+86) 10-6583-7516 or (646) 405-5180
Press spacebar to pause and continue. Press esc to stop.